Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Revenue (2016 - 2025)

Historic Revenue for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to $288.1 million.

  • Ascendis Pharma A's Revenue rose 5503.55% to $288.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $823.0 million, marking a year-over-year increase of 10978.03%. This contributed to the annual value of $813.8 million for FY2025, which is 10943.23% up from last year.
  • According to the latest figures from Q4 2025, Ascendis Pharma A's Revenue is $288.1 million, which was up 5503.55% from $249.7 million recorded in Q3 2025.
  • Ascendis Pharma A's 5-year Revenue high stood at $325.7 million for Q4 2023, and its period low was $899852.1 during Q1 2021.
  • Moreover, its 5-year median value for Revenue was $51.9 million (2023), whereas its average is $91.8 million.
  • Per our database at Business Quant, Ascendis Pharma A's Revenue tumbled by 7629.3% in 2022 and then soared by 129434.92% in 2023.
  • Over the past 5 years, Ascendis Pharma A's Revenue (Quarter) stood at $98.5 million in 2021, then plummeted by 76.29% to $23.4 million in 2022, then surged by 1294.35% to $325.7 million in 2023, then crashed by 42.94% to $185.8 million in 2024, then skyrocketed by 55.04% to $288.1 million in 2025.
  • Its Revenue stands at $288.1 million for Q4 2025, versus $249.7 million for Q3 2025 and $178.9 million for Q2 2025.